ImpediMed Ltd - Company Profile
Powered by 
All the sales intelligence you need on ImpediMed Ltd in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how ImpediMed Ltd fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with ImpediMed Ltd.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Business Description
ImpediMed Ltd (ImpediMed) develops innovative devices that utilize bioimpedance spectroscopy (BIS) for non-invasive clinical assessment and monitoring of fluid status and tissue composition in patients. The company's solutions are designed to address significant healthcare challenges, with a particular focus on secondary lymphedema, including breast cancer-related lymphedema (BCRL).
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
R&D Overview
ImpediMed's research and development initiatives are centered around expanding the applications of their bioimpedance spectroscopy (BIS) technology, primarily targeting secondary lymphoedema with a focus on breast cancer-related lymphoedema. The company is actively working to broaden its product portfolio by developing new applications for existing regulatory clearances, such as body composition and heart failure management. This expansion is supported by partnerships with researchers in grant-funded trials to generate the necessary evidence for clinician adoption. ImpediMed follows a structured framework for product development, from ideation to commercialization, ensuring a disciplined approach to innovation. The company has also introduced SOZO Pro, a next-generation platform designed to enhance fluid and body composition monitoring across broader clinical settings, including heart failure and weight management. These initiatives reflect the scalability and value of it's core technology across multiple disease states, underscoring the company's commitment to revolutionizing patient care through clinically validated, secure platform technology.
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer